Miglustat Axunio

Miglustat, the active ingredient in Miglustat Axunio, is a glucosylceramide synthase inhibitor presented as an unknown/unknown for oral use. It treats Gaucher disease type 1 and Niemann-Pick disease type C. GNH USA supplies Miglustat Axunio as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Miglustat is used in substrate reduction therapy for lysosomal storage disorders.

- Gaucher disease type 1: reduces accumulation of glucocerebroside, helping improve hematologic and organ manifestations. - Niemann-Pick disease type C: decreases synthesis of glycosphingolipids, supporting neurological and systemic symptom management.

Miglustat may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Diarrhea: frequent loose stools, often mild to moderate. - Nausea: sensation of queasiness, may occur after dosing. - Weight loss: gradual reduction in body weight. - Abdominal pain: discomfort or cramps in the stomach area.

Serious or Rare Side Effects: - Pancreatitis: inflammation of the pancreas, presenting with severe abdominal pain. - Severe hypersensitivity reactions: rash, swelling, or anaphylaxis. - Liver enzyme elevation: significant increase in hepatic transaminases.

Before initiating therapy, clinicians should consider several safety measures.

- Renal function monitoring: assess kidney parameters before and during therapy. - Gastrointestinal tolerance: advise patients to take with food to reduce diarrhea. - Weight monitoring: track body weight regularly, especially in pediatric patients. - Pregnancy considerations: evaluate risk vs benefit; use only if clearly needed. - Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Miglustat can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Concomitant use with strong CYP3A4 inducers: may reduce miglustat exposure. - Co-administration with other substrate reduction agents: risk of additive toxicity.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may decrease absorption; separate dosing by at least 2 hours. - High‑fat meals: can reduce bioavailability; advise consistent meal patterns. - Diabetic medications: miglustat may affect glucose tolerance; monitor blood sugar.